$VRDN
Viridian Therapeutics, Inc.\DE Stock $vrdn

$vrdn Overview Financials Valuation SEC Filings Company Website

2022 Q1 Form 10-Q Financial Statement

#000159075022000007 Filed on May 13, 2022

Income Statement

Concept	2022 Q1	2021 Q1
Revenue	$216.0K	$1.451M
YoY Change	-85.11%	75.24%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$8.359M	$6.160M
YoY Change	35.7%	126.47%
% of Gross Profit
Research & Development	$17.75M	$13.81M
YoY Change	28.54%	126.22%
% of Gross Profit
Depreciation & Amortization	$40.00K	$33.00K
YoY Change	21.21%	-51.47%
% of Gross Profit
Operating Expenses	$26.11M	$19.97M
YoY Change	30.75%	126.22%
Operating Profit	-$25.89M	-$18.52M
YoY Change	39.83%	131.5%
Interest Expense	$196.0K	$60.00K
YoY Change	226.67%	-220.0%
% of Operating Profit
Other Income/Expense, Net	$196.0K	$55.00K
YoY Change	256.36%	-42.11%
Pretax Income	-$25.69M	-$18.46M
YoY Change	39.18%	129.6%
Income Tax
% Of Pretax Income
Net Earnings	-$25.69M	-$18.46M
YoY Change	39.18%	129.49%
Net Earnings / Revenue	-11894.91%	-1272.23%
Basic Earnings Per Share	-$0.98	-$2.91
Diluted Earnings Per Share	-$0.98	-$2.91
COMMON SHARES
Basic Shares Outstanding	26.13M shares	6.336M shares
Diluted Shares Outstanding	26.13M shares	6.336M shares

Balance Sheet

Concept	2022 Q1	2021 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$175.4M	$117.1M
YoY Change	49.81%	224.38%
Cash & Equivalents	$30.86M	$46.49M
Short-Term Investments	$144.6M	$70.60M
Other Short-Term Assets	$3.439M	$3.100M
YoY Change	10.94%	40.91%
Inventory
Prepaid Expenses
Receivables	$522.0K	$1.400M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$179.4M	$121.5M
YoY Change	47.6%	216.98%
LONG-TERM ASSETS
Property, Plant & Equipment	$691.0K	$148.0K
YoY Change	366.89%	-66.59%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$1.542M	$1.000K
YoY Change	154100.0%
Total Long-Term Assets	$3.776M	$1.298M
YoY Change	190.91%	83.07%
TOTAL ASSETS
Total Short-Term Assets	$179.4M	$121.5M
Total Long-Term Assets	$3.776M	$1.298M
Total Assets	$183.2M	$122.8M
YoY Change	49.12%	214.55%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.538M	$3.384M
YoY Change	-25.0%	107.73%
Accrued Expenses	$11.56M	$12.76M
YoY Change	-9.43%	317.81%
Deferred Revenue	$288.0K	$288.0K
YoY Change	0.0%
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$14.39M	$16.44M
YoY Change	-12.47%	89.77%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change		-100.0%
Other Long-Term Liabilities	$1.060M	$33.00K
YoY Change	3112.12%
Total Long-Term Liabilities	$1.060M	$33.00K
YoY Change	3112.12%	-99.03%
TOTAL LIABILITIES
Total Short-Term Liabilities	$14.39M	$16.44M
Total Long-Term Liabilities	$1.060M	$33.00K
Total Liabilities	$16.52M	$16.83M
YoY Change	-1.85%	39.7%
SHAREHOLDERS EQUITY
Retained Earnings	-$384.0M	-$297.3M
YoY Change	29.16%	68.73%
Common Stock	$272.0K	$72.00K
YoY Change	277.78%	-86.44%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$166.6M	$106.0M
YoY Change
Total Liabilities & Shareholders Equity	$183.2M	$122.8M
YoY Change	49.12%	214.55%

Cashflow Statement

Concept	2022 Q1	2021 Q1
OPERATING ACTIVITIES
Net Income	-$25.69M	-$18.46M
YoY Change	39.18%	129.49%
Depreciation, Depletion And Amortization	$40.00K	$33.00K
YoY Change	21.21%	-51.47%
Cash From Operating Activities	-$21.04M	-$11.54M
YoY Change	82.36%	36.41%
INVESTING ACTIVITIES
Capital Expenditures	$179.0K	$15.00K
YoY Change	1093.33%
Acquisitions
YoY Change
Other Investing Activities	$9.042M	$10.89M
YoY Change	-16.97%	444.5%
Cash From Investing Activities	$8.863M	$10.87M
YoY Change	-18.48%	443.33%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$738.0K	$1.259M
YoY Change	-41.38%	-92.89%
NET CHANGE
Cash From Operating Activities	-$21.04M	-$11.54M
Cash From Investing Activities	$8.863M	$10.87M
Cash From Financing Activities	$738.0K	$1.259M
Net Change In Cash	-$11.44M	$592.0K
YoY Change	-2032.6%	-94.74%
FREE CASH FLOW
Cash From Operating Activities	-$21.04M	-$11.54M
Capital Expenditures	$179.0K	$15.00K
Free Cash Flow	-$21.22M	-$11.55M
YoY Change	83.67%	36.59%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001590750
CY2022Q1	dei	Amendment Flag AmendmentFlag	false
CY2022Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2022Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022Q1	dei	Entity Registrant Name EntityRegistrantName	Viridian Therapeutics, Inc./DE
CY2021Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2021-01-31#AccruedLiabilitiesCurrent
CY2022Q1	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2021-01-31#AccruedLiabilitiesCurrent
CY2022Q1	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2021-01-31#AccruedLiabilitiesCurrent
CY2022Q1	us-gaap	Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesNoncurrent
CY2022Q1	dei	Document Type DocumentType	10-Q
CY2022Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2022Q1	dei	Document Period End Date DocumentPeriodEndDate	2022-03-31
CY2022Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2022Q1	dei	Entity File Number EntityFileNumber	001-36483
CY2022Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2022Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2022Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	47-1187261
CY2022Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	221 Crescent Street, Suite 401,
CY2022Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Waltham
CY2022Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	MA
CY2022Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	02453
CY2022Q1	dei	City Area Code CityAreaCode	617
CY2022Q1	dei	Local Phone Number LocalPhoneNumber	272-4600
CY2022Q1	dei	Security12b Title Security12bTitle	Common Stock, $0.01 par value per share
CY2022Q1	dei	Trading Symbol TradingSymbol	VRDN
CY2022Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2022Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2022Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2022Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2022Q1	dei	Entity Shell Company EntityShellCompany	false
CY2022Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	27927423	shares
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	30858000	USD
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	42299000	USD
CY2022Q1	us-gaap	Short Term Investments ShortTermInvestments	144570000	USD
CY2021Q4	us-gaap	Short Term Investments ShortTermInvestments	154666000	USD
CY2022Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3439000	USD
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2747000	USD
CY2022Q1	us-gaap	Contract With Customer Asset Net ContractWithCustomerAssetNet	522000	USD
CY2021Q4	us-gaap	Contract With Customer Asset Net ContractWithCustomerAssetNet	451000	USD
CY2022Q1	us-gaap	Assets Current AssetsCurrent	179389000	USD
CY2021Q4	us-gaap	Assets Current AssetsCurrent	200163000	USD
CY2022Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	691000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	375000	USD
CY2022Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1543000	USD
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1680000	USD
CY2022Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1542000	USD
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1491000	USD
CY2022Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2022Q1	us-gaap	Assets Assets	183165000	USD
CY2021Q4	us-gaap	Assets Assets	203709000	USD
CY2022Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	2538000	USD
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2329000	USD
CY2022Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	11560000	USD
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	11018000	USD
CY2022Q1	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	288000	USD
CY2021Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	289000	USD
CY2022Q1	us-gaap	Liabilities Current LiabilitiesCurrent	14386000	USD
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	13636000	USD
CY2022Q1	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	1077000	USD
CY2021Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	1149000	USD
CY2022Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1060000	USD
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1208000	USD
CY2022Q1	us-gaap	Liabilities Liabilities	16523000	USD
CY2021Q4	us-gaap	Liabilities Liabilities	15993000	USD
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2022Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	27169422	shares
CY2022Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	27169422	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	23924004	shares
CY2022Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	23924004	shares
CY2022Q1	us-gaap	Common Stock Value CommonStockValue	272000	USD
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	239000	USD
CY2022Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	439187000	USD
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	412101000	USD
CY2022Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-935000	USD
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-157000	USD
CY2022Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-383993000	USD
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-358300000	USD
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	166642000	USD
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	187716000	USD
CY2022Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	183165000	USD
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	203709000	USD
CY2022Q1	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	216000	USD
CY2021Q1	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	1451000	USD
CY2022Q1	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	17746000	USD
CY2021Q1	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	13806000	USD
CY2022Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	8359000	USD
CY2021Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6160000	USD
CY2022Q1	us-gaap	Operating Expenses OperatingExpenses	26105000	USD
CY2021Q1	us-gaap	Operating Expenses OperatingExpenses	19966000	USD
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-25889000	USD
CY2021Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-18515000	USD
CY2022Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	196000	USD
CY2021Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	55000	USD
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-25693000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-18460000	USD
CY2022Q1	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-778000	USD
CY2021Q1	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-13000	USD
CY2022Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-26471000	USD
CY2021Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-18473000	USD
CY2022Q1	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-25693000	USD
CY2022Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-25693000	USD
CY2021Q1	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-18460000	USD
CY2021Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-18460000	USD
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.98
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.98
CY2021Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.91
CY2021Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.91
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	26126092	shares
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	26126092	shares
CY2021Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	6336347	shares
CY2021Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	6336347	shares
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	187716000	USD
CY2022Q1	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	0	USD
CY2022Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	667000	USD
CY2022Q1	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	71000	USD
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	4659000	USD
CY2022Q1	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-778000	USD
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-25693000	USD
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	166642000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	120037000	USD
CY2021Q1	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	0	USD
CY2021Q1	mgen	Stock Issued During Period Value Warrants Exercised Value StockIssuedDuringPeriodValueWarrantsExercisedValue	940000	USD
CY2021Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	307000	USD
CY2021Q1	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	12000	USD
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3175000	USD
CY2021Q1	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-13000	USD
CY2022Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-274000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-18460000	USD
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	105998000	USD
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-25693000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-18460000	USD
CY2022Q1	us-gaap	Share Based Compensation ShareBasedCompensation	4659000	USD
CY2021Q1	us-gaap	Share Based Compensation ShareBasedCompensation	3175000	USD
CY2022Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	40000	USD
CY2021Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	33000	USD
CY2021Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-232000	USD
CY2022Q1	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-47000	USD
CY2021Q1	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	5000	USD
CY2022Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	740000	USD
CY2021Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	3622000	USD
CY2022Q1	us-gaap	Increase Decrease In Contract With Customer Asset IncreaseDecreaseInContractWithCustomerAsset	71000	USD
CY2021Q1	us-gaap	Increase Decrease In Contract With Customer Asset IncreaseDecreaseInContractWithCustomerAsset	-1382000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-11539000	USD
CY2022Q1	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	5192000	USD
CY2022Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-72000	USD
CY2021Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-149000	USD
CY2022Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	31000	USD
CY2022Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	31000	USD
CY2021Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	2715000	USD
CY2022Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	483000	USD
CY2021Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	3160000	USD
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-21042000	USD
CY2021Q1	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	56652000	USD
CY2022Q1	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	14234000	USD
CY2021Q1	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	67539000	USD
CY2022Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	179000	USD
CY2021Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	15000	USD
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	8863000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	10872000	USD
CY2022Q1	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	0	USD
CY2021Q1	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	940000	USD
CY2022Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	667000	USD
CY2021Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	307000	USD
CY2022Q1	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	71000	USD
CY2021Q1	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	12000	USD
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	738000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1259000	USD
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-11441000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	592000	USD
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	42299000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	45897000	USD
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	30858000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	46489000	USD
CY2022Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	177000	USD
CY2021Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	0	USD
CY2022Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-384000000.0	USD
CY2022Q1	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	175400000	USD
CY2022Q1	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2022Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s condensed consolidated financial statements are prepared in accordance with U.S. GAAP, which requires it to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and contingent liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, the accrual for clinical trial costs and other outsourced research and development expenses, and the valuation of share-based awards. Although these estimates are based on the Company’s knowledge of current events and actions it may take in the future, actual results may ultimately differ from these estimates and assumptions.</span></div>
CY2022Q1	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Credit Risk</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash equivalents, which include short-term investments that have maturities of less than three months. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts. The Company invests its excess cash primarily in deposits and money market funds held with one financial institution.</span></div>
CY2021Q1	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	USD
CY2022Q1	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	USD
CY2022Q1	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	USD
CY2022Q1	us-gaap	Income Tax Examination Penalties And Interest Expense IncomeTaxExaminationPenaltiesAndInterestExpense	0	USD
CY2021Q1	us-gaap	Income Tax Examination Penalties And Interest Expense IncomeTaxExaminationPenaltiesAndInterestExpense	0	USD
CY2021Q1	us-gaap	Debt Securities Available For Sale Realized Gain Loss DebtSecuritiesAvailableForSaleRealizedGainLoss	4000	USD
CY2022Q1	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2022Q1	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	176263000	USD
CY2022Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	1000	USD
CY2022Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	936000	USD
CY2022Q1	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	175328000	USD
CY2021Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	197022000	USD
CY2021Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	6000	USD
CY2021Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	163000	USD
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	196865000	USD
CY2022Q1	us-gaap	Debt Securities Available For Sale Realized Gain Loss DebtSecuritiesAvailableForSaleRealizedGainLoss	0	USD
CY2022Q1	mgen	Lessee Operating Lease Number Of Renewal Terms LesseeOperatingLeaseNumberOfRenewalTerms	3	renewal_term
CY2022Q1	us-gaap	Debt Securities Available For Sale Term DebtSecuritiesAvailableForSaleTerm	P24M
CY2022Q1	mgen	Accrued Outsourcing Clinicaland Preclinical Studies AccruedOutsourcingClinicalandPreclinicalStudies	8647000	USD
CY2021Q4	mgen	Accrued Outsourcing Clinicaland Preclinical Studies AccruedOutsourcingClinicalandPreclinicalStudies	6316000	USD
CY2022Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1548000	USD
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	3652000	USD
CY2022Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	579000	USD
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	520000	USD
CY2022Q1	mgen	Accrued Legal Fees Current AccruedLegalFeesCurrent	272000	USD
CY2021Q4	mgen	Accrued Legal Fees Current AccruedLegalFeesCurrent	80000	USD
CY2022Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	131000	USD
CY2021Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	140000	USD
CY2022Q1	mgen	Accrued Liabilityof Warrantson Temporary Equity AccruedLiabilityofWarrantsonTemporaryEquity	100000	USD
CY2021Q4	mgen	Accrued Liabilityof Warrantson Temporary Equity AccruedLiabilityofWarrantsonTemporaryEquity	100000	USD
CY2022Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	283000	USD
CY2022Q1	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	100000	USD
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	210000	USD
CY2022Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	11560000	USD
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	11018000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Renewal Term LesseeOperatingLeaseRenewalTerm	P3Y
CY2021Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1600000	USD
CY2021Q1	us-gaap	Lessee Operating Lease Discount Rate LesseeOperatingLeaseDiscountRate	0.06
CY2021Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P12M
CY2021Q2	us-gaap	Lessor Operating Lease Payments To Be Received LessorOperatingLeasePaymentsToBeReceived	200000	USD
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	100000	USD
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	100000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Discount Rate LesseeOperatingLeaseDiscountRate	0.06
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	1800000	USD
CY2022Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	600000	USD
CY2022Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1100000	USD
CY2021Q1	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	100000	USD
CY2022Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2022Q1	mgen	Operating Leases Operating Expense OperatingLeasesOperatingExpense	51000	USD
CY2021Q1	mgen	Operating Leases Operating Expense OperatingLeasesOperatingExpense	54000	USD
CY2022Q1	mgen	Capital Stock Shares Authorized CapitalStockSharesAuthorized	205000000	shares
CY2022Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2022Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2022Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2022Q1	mgen	Common Stock Voteper Share CommonStockVoteperShare	1	vote
CY2022Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2022Q1	mgen	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights Net ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsNet	420629	shares
CY2021Q4	mgen	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights Net ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsNet	420629	shares
CY2022Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	15.91
CY2022Q1	mgen	Class Of Warrant Or Right Exercised In Period ClassOfWarrantOrRightExercisedInPeriod	0	shares
CY2022Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P3Y2M4D
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	4801711	shares
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	990338	shares
CY2022Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4659000	USD
CY2021Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3175000	USD
CY2022Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	56300000	USD
CY2022Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	20935925	shares
CY2021Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	27251218	shares

Files In Submission

Name	View Source	Status
0001590750-22-000007-index-headers.html	Edgar Link	pending
0001590750-22-000007-index.html	Edgar Link	pending
0001590750-22-000007.txt	Edgar Link	pending
0001590750-22-000007-xbrl.zip	Edgar Link	pending
ex311_2022-03.htm	Edgar Link	pending
ex312_2022-03.htm	Edgar Link	pending
ex321_2022-03.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
mgen-20220331.htm	Edgar Link	pending
mgen-20220331.xsd	Edgar Link	pending
mgen-20220331_cal.xml	Edgar Link	unprocessable
mgen-20220331_def.xml	Edgar Link	unprocessable
mgen-20220331_htm.xml	Edgar Link	completed
mgen-20220331_lab.xml	Edgar Link	unprocessable
mgen-20220331_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
vrdn_amendedandrestatedbyl.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$VRDN
Viridian Therapeutics, Inc.\DE Stock $vrdn

2022 Q1 Form 10-Q Financial Statement

#000159075022000007 Filed on May 13, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$VRDN Viridian Therapeutics, Inc.\DE Stock $vrdn

2022 Q1 Form 10-Q Financial Statement

#000159075022000007 Filed on May 13, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$VRDN
Viridian Therapeutics, Inc.\DE Stock $vrdn